04/17/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
3:24 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/10/2024
10:58 AM | Capital International Investors (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
04/09/2024
3:42 PM | CRISPR Therapeutics (Filer)
| Form DEF 14A | |
04/09/2024
3:43 PM | CRISPR Therapeutics (Filer)
| Form DEFA14A | |
04/09/2024
3:47 PM | CRISPR Therapeutics (Filer)
| Form ARS | |
03/27/2024
3:30 PM | CRISPR Therapeutics (Filer)
| Form PRE 14A | |
|
03/27/2024
3:30 PM | CRISPR Therapeutics (Filer)
| Form PRE 14A | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/22/2024
3:02 PM | CRISPR Therapeutics (Subject)
Morrow Phuong Khanh (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
3:43 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/12/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/12/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2024
5:39 PM | CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
4:45 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2024
6:45 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/21/2024
6:50 AM | CRISPR Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/16/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/15/2024
3:30 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/13/2024
4:22 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/13/2024
7:44 AM | CRISPR Therapeutics (Filer)
| Form 424B5 | |
02/13/2024
5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/13/2024
5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/12/2024
5:22 PM | CRISPR Therapeutics (Subject)
Nikko Asset Management Americas, Inc. (Filed by)
| Form SC 13G/A | |
02/05/2024
5:08 AM | CRISPR Therapeutics (Subject)
Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
| Form SC 13G/A | |
01/31/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
3:00 PM | ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
01/18/2024
4:45 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2024
10:36 AM | ARK Investment Management LLC (Filed by)
CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
12/15/2023
7:58 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/13/2023
8:22 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/08/2023
12:16 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/16/2023
6:21 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
3:42 PM | CRISPR Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2023
3:33 PM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2023
4:52 PM | CRISPR Therapeutics (Issuer)
Morrow Phuong Khanh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad) Don't Buy Bullion or Mining Stocks. Do THIS Instead
As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. |
10/17/2023
4:52 PM | CRISPR Therapeutics (Issuer)
Prasad Raju (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
4:48 PM | CRISPR Therapeutics (Issuer)
KASINGER JAMES R. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
4:51 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/07/2023
7:39 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/09/2023
4:33 PM | CRISPR Therapeutics (Issuer)
Fardis Maria (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:34 PM | CRISPR Therapeutics (Issuer)
Fleming Harold Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:34 PM | CRISPR Therapeutics (Issuer)
Greene John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:36 PM | CRISPR Therapeutics (Issuer)
High Katherine A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:36 PM | CRISPR Therapeutics (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:48 PM | Behbahani Ali (Reporting)
CRISPR Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
4:56 PM | CRISPR Therapeutics (Issuer)
George Simeon (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/09/2023
6:07 AM | CRISPR Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/01/2023
4:44 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2023
3:38 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/25/2023
4:35 PM | CRISPR Therapeutics (Issuer)
Morrow Phuong Khanh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2023
2:23 PM | CRISPR Therapeutics (Subject)
Smith Brendan (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/27/2023
4:37 PM | CRISPR Therapeutics (Issuer)
Kulkarni Samarth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2023
3:38 PM | CRISPR Therapeutics (Filer)
| Form ARS | |
04/25/2023
3:28 PM | CRISPR Therapeutics (Subject)
Kulkarni Samarth (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
